Mandate

Vinge advises Industrifonden in connection with its investment in solar cells company, Sol Voltaics

July 04, 2011

Vinge has advised Stiftelsen Industrifonden in connection with its SEK 18.5 million investment in the solar cells company, Sol Voltaics. Sol Voltaics has developed a completely new type of material which can significant reduce the cost of producing electricity from solar cells. The total amount of the issue is SEK 40 million and the capital will be used for the future development of the company’s products. Sol Voltaics has developed a new material and a new production method for the manufacture of solar cells. In brief, it is based upon the rapid production of nano threads of gallium arsenide (GaAs), where each thread is a solar cell. This material has been widely recoginsed for some time as the best way of manufacturing solar cells although up to now it has been too expensive to use. Sol Volatics has now developed a method which can radically reduce the costs associated with the aforementioned method.

Vinge’s team consisted of Johan Larsson (project manager) and Claes Henriksson. Johan Winnerblad was the responsible partner.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025